A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States

A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States

Background. Chimeric antigen receptor (CAR) T-cell therapies are approved as second-line (2L) or later therapy for diffuse large B-cell lymphoma (DLBCL). Recently, bispecific T-cell antibodies (BsAbs) have been approved as third-line (3L) treatments. The cost-effectiveness of different treatment seq...

Full description

Saved in:
Bibliographic Details
Main Authors: Anik R. Patel, Bradley Kievit, Ken Hasegawa, Markqayne Ray, Rishika Sharma, Sarahmaria Hofmann, Rob Blissett, Frederick L. Locke
Format: Article
Language:English
Published: SAGE Publishing 2025-06-01
Series:MDM Policy & Practice
Online Access:https://doi.org/10.1177/23814683251345780
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items